Related Experiment Video

Updated: May 18, 2026

Controllable Ion Channel Expression through Inducible Transient Transfection
10:00

Controllable Ion Channel Expression through Inducible Transient Transfection

Published on: February 17, 2017

Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells

Xin Ma1, Yanfei Cai, Dongxu He

  • 1School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu 214122, China.

Proceedings of the National Academy of Sciences of the United States of America
|September 19, 2012
PubMed

Insights

Targeting the TRPC5 channel can reverse multidrug resistance in cancer. Suppressing TRPC5 reduces P-glycoprotein (P-gp) induction, overcoming chemotherapy resistance and inhibiting tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in cancer is a major challenge in chemotherapy.
  • P-glycoprotein (P-gp) is a key efflux pump overexpressed in MDR cancer cells, reducing drug efficacy.
  • Identifying novel targets to overcome MDR is crucial for improving cancer treatment outcomes.

Purpose of the Study:

  • To investigate the role of TRPC5 channels in the development of adriamycin resistance in breast cancer.
  • To explore the potential of TRPC5 as a therapeutic target to reverse multidrug resistance.
  • To elucidate the signaling pathway linking TRPC5 activity to P-gp expression.

Main Methods:

  • Utilized the adriamycin-resistant breast cancer cell line MCF-7/ADM.
  • Assessed the effect of suppressing TRPC5 activity and expression on P-gp levels and adriamycin sensitivity.
  • Evaluated TRPC5 inhibition in an in vivo athymic nude mouse model with adriamycin-resistant human breast tumor xenografts.
  • Identified the role of Nuclear factor of activated T cells isoform c3 (NFATc3) as a transcriptional regulator.

Main Results:

  • TRPC5 was found to be overexpressed along with P-gp in adriamycin-resistant MCF-7/ADM cells.
  • Suppression of TRPC5 significantly reduced P-gp induction and reversed adriamycin resistance in vitro.
  • In vivo studies showed that TRPC5 suppression decreased the growth of adriamycin-resistant tumor xenografts.
  • NFATc3 was identified as the transcriptional factor mediating the link between TRPC5 and P-gp production.

Conclusions:

  • TRPC5 plays a critical role in the induction of P-gp in drug-resistant cancer cells.
  • The TRPC5-NFATc3-P-gp signaling cascade is essential for mediating adriamycin resistance.
  • Targeting TRPC5 presents a promising strategy to overcome multidrug resistance in breast cancer chemotherapy.

More Related Videos

Expression and Purification of the Human Lipid-sensitive Cation Channel TRPC3 for Structural Determination by Single-particle Cryo-electron Microscopy08:27

Expression and Purification of the Human Lipid-sensitive Cation Channel TRPC3 for Structural Determination by Single-particle Cryo-electron Microscopy

Published on: January 7, 2019

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...